Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Thursday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research report on Friday, January 10th.

Aptose Biosciences Trading Up 0.4 %

Aptose Biosciences stock opened at $0.21 on Thursday. The company has a fifty day simple moving average of $0.24 and a 200-day simple moving average of $0.39. The stock has a market cap of $12.46 million, a P/E ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.